Maxim Group set a $12.00 price target on Cytosorbents (NASDAQ:CTSO) in a research note released on Thursday, December 21st. The firm currently has a buy rating on the medical research company’s stock.
Several other analysts have also recently issued reports on CTSO. ValuEngine raised shares of Cytosorbents from a sell rating to a hold rating in a research note on Wednesday, September 6th. HC Wainwright reaffirmed a buy rating and set a $13.00 price target on shares of Cytosorbents in a research report on Tuesday, September 26th. Finally, B. Riley reaffirmed a buy rating and set a $11.25 price target on shares of Cytosorbents in a research report on Friday, November 10th. One investment analyst has rated the stock with a hold rating and five have assigned a buy rating to the company’s stock. Cytosorbents has an average rating of Buy and a consensus price target of $10.60.
Shares of Cytosorbents (NASDAQ CTSO) opened at $7.80 on Thursday. Cytosorbents has a 12 month low of $3.30 and a 12 month high of $7.85. The stock has a market cap of $223.79, a price-to-earnings ratio of -20.53 and a beta of -0.54. The company has a current ratio of 3.36, a quick ratio of 3.17 and a debt-to-equity ratio of 0.73.
In related news, CFO Kathleen P. Bloch sold 32,400 shares of the stock in a transaction dated Monday, January 8th. The shares were sold at an average price of $7.30, for a total transaction of $236,520.00. Following the sale, the chief financial officer now owns 248,638 shares in the company, valued at $1,815,057.40. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, COO Vincent Capponi sold 4,000 shares of the stock in a transaction dated Monday, November 27th. The stock was sold at an average price of $7.00, for a total transaction of $28,000.00. Following the sale, the chief operating officer now owns 271,062 shares in the company, valued at approximately $1,897,434. The disclosure for this sale can be found here. Corporate insiders own 5.60% of the company’s stock.
Several large investors have recently made changes to their positions in CTSO. Fortaleza Asset Management Inc. boosted its holdings in Cytosorbents by 81.6% during the third quarter. Fortaleza Asset Management Inc. now owns 23,375 shares of the medical research company’s stock worth $145,000 after buying an additional 10,500 shares in the last quarter. PNC Financial Services Group Inc. boosted its holdings in Cytosorbents by 145.2% during the second quarter. PNC Financial Services Group Inc. now owns 38,000 shares of the medical research company’s stock worth $163,000 after buying an additional 22,500 shares in the last quarter. Finally, Wealthcare Advisory Partners LLC bought a new stake in Cytosorbents during the third quarter worth approximately $365,000. Institutional investors own 8.65% of the company’s stock.
ILLEGAL ACTIVITY NOTICE: “Cytosorbents (NASDAQ:CTSO) PT Set at $12.00 by Maxim Group” was first reported by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are reading this piece of content on another domain, it was stolen and reposted in violation of US & international trademark & copyright laws. The correct version of this piece of content can be viewed at https://www.dispatchtribunal.com/2018/01/14/cytosorbents-ctso-given-a-12-00-price-target-at-maxim-group.html.
Cytosorbents Company Profile
CytoSorbents Corporation is a critical care focused immunotherapy company. The Company is engaged in commercializing its product, CytoSorb, which is a blood purification technology with focus in preventing or treating multiple organ failure. The Company’s purification technologies are based on biocompatible, porous polymer beads that remove toxic substances from blood and other bodily fluids by pore capture and surface adsorption.
Receive News & Ratings for Cytosorbents Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cytosorbents and related companies with MarketBeat.com's FREE daily email newsletter.